Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R.

J Immunol. 2019 May 15;202(10):2888-2906. doi: 10.4049/jimmunol.1800583. Epub 2019 Apr 15.

2.

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

Hatz S, Spangler S, Bender A, Studham M, Haselmayer P, Lacoste AMB, Willis VC, Martin RL, Gurulingappa H, Betz U.

PLoS One. 2019 Apr 8;14(4):e0214619. doi: 10.1371/journal.pone.0214619. eCollection 2019.

3.

Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.

Aqrawi LA, Ivanchenko M, Björk A, Ramírez Sepúlveda JI, Imgenberg-Kreuz J, Kvarnström M, Haselmayer P, Jensen JL, Nordmark G, Chemin K, Skarstein K, Wahren-Herlenius M.

Clin Exp Immunol. 2018 Jun;192(3):259-270. doi: 10.1111/cei.13118. Epub 2018 Mar 24.

PMID:
29453859
4.

A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.

Haselmayer P, Vigolo M, Nys J, Schneider P, Hess H.

Eur J Immunol. 2017 Jun;47(6):1075-1085. doi: 10.1002/eji.201746934. Epub 2017 Apr 24.

5.

Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.

Bender AT, Gardberg A, Pereira A, Johnson T, Wu Y, Grenningloh R, Head J, Morandi F, Haselmayer P, Liu-Bujalski L.

Mol Pharmacol. 2017 Mar;91(3):208-219. doi: 10.1124/mol.116.107037. Epub 2017 Jan 6.

PMID:
28062735
6.

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.

Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H.

Front Immunol. 2014 May 22;5:233. doi: 10.3389/fimmu.2014.00233. eCollection 2014.

7.

A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome.

Gladigau G, Haselmayer P, Scharrer I, Munder M, Prinz N, Lackner K, Schild H, Stein P, Radsak MP.

PLoS One. 2012;7(7):e42176. doi: 10.1371/journal.pone.0042176. Epub 2012 Jul 31.

8.

Signaling pathways of the TREM-1- and TLR4-mediated neutrophil oxidative burst.

Haselmayer P, Daniel M, Tertilt C, Salih HR, Stassen M, Schild H, Radsak MP.

J Innate Immun. 2009;1(6):582-91. doi: 10.1159/000231973. Epub 2009 Jul 30.

9.

Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.

Radsak MP, Taube C, Haselmayer P, Tenzer S, Salih HR, Wiewrodt R, Buhl R, Schild H.

Clin Dev Immunol. 2007;2007:52040. doi: 10.1155/2007/52040.

10.

TREM-1 ligand expression on platelets enhances neutrophil activation.

Haselmayer P, Grosse-Hovest L, von Landenberg P, Schild H, Radsak MP.

Blood. 2007 Aug 1;110(3):1029-35. Epub 2007 Apr 23.

11.

Herpes virus entry mediator synergizes with Toll-like receptor mediated neutrophil inflammatory responses.

Haselmayer P, Tenzer S, Kwon BS, Jung G, Schild H, Radsak MP.

Immunology. 2006 Nov;119(3):404-11.

12.

Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses.

Warger T, Hilf N, Rechtsteiner G, Haselmayer P, Carrick DM, Jonuleit H, von Landenberg P, Rammensee HG, Nicchitta CV, Radsak MP, Schild H.

J Biol Chem. 2006 Aug 11;281(32):22545-53. Epub 2006 Jun 5.

Supplemental Content

Loading ...
Support Center